Boston Scientific (BSX) exec says goal is flat pricing each year, but flat to down 1% is what to expect on go forward basis - JPM conference

• Exec says China won't grow 20% like it used to, but confident it will grow in teens going forward.

Boston Scientific's executive comments suggest a cautious outlook on pricing stability, with expectations for flat to slightly declining revenue in the near term. This realism about growth prospects, particularly in key markets like China, may signal challenges ahead for the company's margins and could influence investor sentiment regarding the stock's short-term performance.